Humanised monoclonal antibody against CD80, a co-stimulatory molecule found transiently on some normal lymphocytes, but also expressed by certain B-cell lymphomas. Following promising initial studies, it is currently undergoing phase III trials in the treatment of certain types of relapsed B-cell lymphomas.
- ↑ Younes A, Hariharan K, Allen RS, Leigh BR. Initial trials of anti-CD80 monoclonal antibody (Galiximab) therapy for patients with relapsed or refractory follicular lymphoma. Clinical lymphoma. 2003 Mar; 3(4):257-9.
- ↑ Leonard JP, Friedberg JW, Younes A, Fisher D, Gordon LI, Moore J, Czuczman M, Miller T, Stiff P, Cheson BD, Forero-Torres A, Chieffo N, McKinney B, Finucane D, Molina A. A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2007 Jul; 18(7):1216-23.(Link to article – subscription may be required.)